Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant

HIV-1 is a chronic disease managed by strictly adhering to daily antiretroviral therapy (ART). However, not all people living with HIV-1 have access to ART, and those with access may not adhere to treatment regimens increasing viral load and disease progression. Here, a subcutaneous nanofluidic impl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pons-Faudoa, Fernanda P., Trani, Nicola Di, Sizovs, Antons, Shelton, Kathryn A., Momin, Zoha, Bushman, Lane R., Xu, Jiaqiong, Lewis, Dorothy E., Demaria, Sandra, Hawkins, Trevor, Rooney, James F., Marzinke, Mark A., Kimata, Jason T., Anderson, Peter L., Nehete, Pramod N., Arduino, Roberto C., Sastry, K. Jagannadha, Grattoni, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590004/
https://www.ncbi.nlm.nih.gov/pubmed/33080776
http://dx.doi.org/10.3390/pharmaceutics12100981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590004/
https://www.ncbi.nlm.nih.gov/pubmed/33080776
http://dx.doi.org/10.3390/pharmaceutics12100981

Ejemplares similares